Abstract:Introduction For patients presenting with primary Left Ventricular Hypertrophy (LVH), the ESC recommends systematic search for diagnostic clues or "red flags" (cardiac and non-cardiac) that can identify particular treatable disorders and guide rational selection of diagnostic tests. To date, a systematic evaluation of this recommendation has not been performed Purpose We sought to determine prevalence and predictive accuracy of clinical markers (red flags, RF), known to be associated with specific systemic disease in a consecutive cohort of patients with hypertrophic cardiomyopathy (HCM). Methods We studied 210 consecutively genotyped patients (54±21 years, 118 (56% males) referred to our center for the suspicion of primary LVH. Pre-specified RF were categorized into four domains: family history; signs/symptoms; electrocardiography and imaging. Results Of the 210 patients, 84 (40%) were diagnosed with sarcomeric HCM, 56 (27%) with TTR amyloidosis, 44 (21%) with Fabry disease (FD), 7 (4%) with a mitochondrial disease, 4 (2%) with Pompe disease, 4 (2%) with PRKAG2 cardiomyopathy, 3 (1%) with Noonan, 3 (1%) with Friederich's Ataxia, 3 (1%) with LEOPARD and 2 (1%) with Danon disease. A total of 942 RF has been identified in the cohort. Concerning family history, autosomal dominant pattern was specific for sarcomeric HCM (66/84, 79%), whereas X-linked inheritance was frequently observed in Fabry disease (40/44, 91%). Non-sarcomeric causes of HCM were the most prevalent in ages 55yo. Ophthalmological signs/symptoms (22/23) were specifically find in FD, whereas muscolo-skeletal RF were rare and non-specific. Neurological phenotype was prevalent in FD patients (38/44, 86%), as well as in TTR amyloidosis (carpal tunnel in 29/56, (52%)), in mithocondropathies and Friederich's Ataxia. Cutaneous involvement was frequent in FD (12 patients with angiokeratomata) (Tab.1). Giant T waves inversion was the most prevalent ECG alteration, but aspecific (61 patients, 32/84 sarcomeric HCM, 16/44 FD). Short PR interval was found in 24 (12%) of patients and specific for FD (15/44) and mitochondrial disease (3/7). Low QRS voltage was present in 17 (8%) patients, and of these 16 had TTR amyloidosis. Inferior leads Q waves was uncommon and non-specific. Mitral valve disease (SAM and anterior mitral leaflet elongation) and apical LVH were present respectively in 57/210 (28%) and 9/210 (4%) of the patient and were almost entirely observed in sarcomeric HCM. Concentric LVH and severe left posterior wall hypertrophy were extremely specific for non sarcomeric HCM (108/109 cases). Strain apical sparing was useful in the identification of TTR amyloidosis. Conclusions Clinical RF in patients with primary LVH are common and can be highly specific for correct phenotypisation of the patient. An extensive diagnostic work-up should therefore be conducted by the physician to identify potentially treatable primary LVH causes. Funding Acknowledgement Type of funding sources: None.

Incidence and risk factors for development of left ventricular hypertrophy in Fabry disease

Prognostic Implications of Left Ventricular Hypertrophy and Mechanical Function in Fabry Disease: A Longitudinal Cohort Study

The Asian Fabry Cardiomyopathy High-Risk Screening Study 2 (ASIAN-FAME-2): Prevalence of Fabry Disease in Patients with Left Ventricular Hypertrophy

Pre-Hypertrophy Reduction of Diastolic Deformation in Fabry Disease

Reduced Global Longitudinal Strain As a Marker for Early Detection of Fabry Cardiomyopathy

NT-proBNP Reflects Left Ventricular Hypertrophy Rather than Left Ventricular Dilatation or Systolic Dysfunction in Patients with Fabry Disease

Fabry Disease with Acute Myocardial Infarction, Left Ventricular Thrombosis, and Pericardial Effusion

Left ventricular hypertrophy: do not forget Fabry disease. Diagnostic work-up and differential diagnosis

"Interstitial fibrosis is associated with left atrial remodeling and adverse clinical outcomes in selected low-risk patients with hypertrophic cardiomyopathy"

Screening for Fabry disease in patients with left ventricular hypertrophy in China: A multicentre and prospective study

Fabry Disease and the Effectiveness of Enzyme Replacement Therapy (ERT) in Left Ventricular Hypertrophy (LVH) Improvement: A Review and Meta-Analysis

Cardiomyocyte Globotriaosylceramide Accumulation in Adult Male Patients with Fabry Disease and IVS4 + 919g>a GLA Mutation is Progressive with Age and Correlates with Left Ventricular Hypertrophy and Reduced Left Ventricular Ejection Fraction

Impact of enzyme replacement therapy and migalastat on left atrial strain and cardiomyopathy in patients with Fabry disease

Imaging predictors of adverse prognosis in fabry disease cardiomyopathy: a systematic review and meta-analysis

Influence Factors of Left Ventricular Hypertrophy in Incipient Lupus Nephritis Patients

Prevalence and clinical correlates of clinical red flags for rare diseases in consecutive patients presenting with HCM phenotype

Biomarkers Associated with Clinical Manifestations in Fabry Disease Patients with a Late-Onset Cardiac Variant Mutation.

Left ventricular hypertrophy phenotype to predict incident atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis

Anderson-Fabry disease patients with anatomical heart hypertrophy express a higher degree of electrocardiographic hypertrophy compared to hypertrophic cardiomyopathy patients

Cardiac Manifestations in Patients with Classical or Cardiac Subtype of Fabry Disease.

Echocardiographic Strain Abnormalities Precede Left Ventricular Hypertrophy Development in Hypertrophic Cardiomyopathy Mutation Carriers